Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study.

about

Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study.

Item

http://www.wikidata.org/entity/Q47267573

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Breakthrough seizures-Further ...... epileptic Drugs (SANAD) study.

@en

Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs

@nl

type

Item

label

Breakthrough seizures-Further ...... epileptic Drugs (SANAD) study.

@en

Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs

@nl

prefLabel

Breakthrough seizures-Further ...... epileptic Drugs (SANAD) study.

@en

Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs

@nl

P1476

Breakthrough seizures-Further ...... epileptic Drugs (SANAD) study.

@en

P2093

Anthony G Marson

http://www.w3.org/2001/XMLSchema#string

Graham A Powell

http://www.w3.org/2001/XMLSchema#string

P2860

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

A new look at the statistical model identification

Distribution of seizure precipitants among epilepsy syndromes.

Time to 12-month remission and treatment failure for generalised and unclassified epilepsy.

Treatment outcome after failure of a first antiepileptic drug.

Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial.

The frequency and precipitating factors for breakthrough seizures among patients with epilepsy in Uganda

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

Multiple treatment comparisons in epilepsy monotherapy trials.

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

P304

e0190035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0190035

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laura J. Bonnett

Catrin Tudur Smith

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29267375

http://www.w3.org/2001/XMLSchema#string

P932

5739445

http://www.w3.org/2001/XMLSchema#string